ORPHA:91
Aromatase deficiency
Also known as: Congenital estrogen deficiency
Publications
9,383
Trials
0
Interventional, condition-specific
Researchers
1,104
Distinct authors in sample
Gene link
CYP19A1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder that disrupts the synthesis of estradiol, resulting in hirsutism of mothers during gestation of an affected child; pseudohermaphroditism and virilization in women; and tall stature, osteoporosis and obesity in men.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013301
- MeSH:C537436
- OMIM:613546
- UMLS:C1960539
- NCIT:C120144
Additional Mondo synonyms (3)
aromatase deficiency · congenital estrogen deficiency · congenital oestrogen deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — CYP19A1
- LiteraturePresent
9,383 matched papers (6,840 in last 10 years) Source
- Phenotype characterisedPresent
30 HPO annotations (e.g. Female pseudohermaphroditism; Delayed skeletal maturation; Hypergonadotropic hypogonadism) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (CYP19A1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
30
Associated phenotypes · MONDO:0013301
- Female pseudohermaphroditism
- Delayed skeletal maturation
- Hypergonadotropic hypogonadism
- Ovarian cyst
- Primary amenorrhea
Showing 5 of 30 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
1 associated chemical · 12 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- enilconazole · marker/mechanism
Pathways: Steroid hormone biosynthesis; Metabolic pathways; Ovarian steroidogenesis; C19/C18-Steroid hormone biosynthesis, pregnenolone => androstenedione => estrone; Metabolism; Estrogen biosynthesis; Metabolism of steroid hormones; Biological oxidations
Literature
Is anyone studying this?
9,383
9,383 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
9,383 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
6,840 in the last 10 years · low confidence
Phrase hits: 742 · MeSH hits: 0
Who's working on it?
1,104
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Zhang Y15 papers · 2026
State Key Laboratory for Zoonotic Diseases, College of Veterinary Medicine, Jilin University, Changchun 130062, China.
Papers in Europe PMC - 02Li Y11 papers · 2026
Jiangsu Institute of Poultry Science, Chinese Academy of Agricultural Sciences, Yangzhou, 225125, China.
Papers in Europe PMC - 03Li J10 papers · 2026
Key Laboratory for Animal Genetics, Breeding, Reproduction and Molecular Design, College of Animal Science and Technology, Yangzhou University, Yangzhou, 225009, China.
Papers in Europe PMC - 04Liu X9 papers · 2026
The Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an 710003, China; Department of Nutrition, Shanghai Jiai Genetic & IVF Institute, Obstetrics & Gynecology Hospital, Shanghai Medical College, Fudan University, Shanghai 200011, China.
Papers in Europe PMC - 05Liu Y9 papers · 2026
College of Animal Science, Anhui Science and Technology University, Fengyang, Anhui 233100, China.
Papers in Europe PMC - 06Wang Z8 papers · 2026
State Key Laboratory of Mariculture Biobreeding and Sustainable Goods, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao, Shandong 266071, China.
Papers in Europe PMC - 07Chen S6 papers · 2026
Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai 200433, China.
Papers in Europe PMC - 08Wang Y6 papers · 2026
Key Laboratory of Biological Resources and Ecology of Pamirs Plateau of Xinjiang Uygur Autonomous Region, Kashi University, Kashi 844000, China.
Papers in Europe PMC - 09Sun J5 papers · 2026
Key Laboratory for Animal Genetics, Breeding, Reproduction and Molecular Design, College of Animal Science and Technology, Yangzhou University, Yangzhou, 225009, China.
Papers in Europe PMC - 10Wang H5 papers · 2026
College of Animal Science, Anhui Science and Technology University, Fengyang, Anhui 233100, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN68270067·Stopped·Clinical trial for patients with TKI resistant chronic myeloid leukaemia in chronic or accelerated phase
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32813419·No longer recruiting·STAG: effect of the drug AZD4017 on bone density in post-menopausal women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11469487·No longer recruiting·Aromatase inhibitors in girls: Anastrozole combined to the LHRH analogue leuprorelin in Girls with early or precocious puberty and a compromised growth potential
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN06129599·No longer recruiting·Traditional Chinese medicine for the management of aromatase inhibitor-associated musculoskeletal symptoms
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99654100·No longer recruiting·A first-in-human phase I/II study to evaluate the safety, tolerability, anti-cancer activity and metabolism of SN38-SPL9111 (DEP®-SN38), an SN38 dendrimer conjugate, in patients with advanced solid tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN66310879·No longer recruiting·A first-in-human study of HMB-001 in patients with Glanzmann thrombasthenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29375062·No longer recruiting·Vaginal colonization by orally consumed lactobacilli in healthy women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36746902·No longer recruiting·Pharmacokinetics and safety of IV Injection of OCTA-C1-INH in hereditary angioedema
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Aromatase deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Aromatase deficiency" OR "Congenital estrogen deficiency" OR "congenital oestrogen deficiency") OR ("CYP19A1" OR "CYP19A1 syndrome" OR "CYP19A1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Aromatase deficiency" OR "Congenital estrogen deficiency" OR "congenital oestrogen deficiency"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (9383) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T12:23:11.239Z
